A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Stopped Replaced with another clinical trial.
Conditions
- Relapsed or Refractory Follicular Lymphoma
Interventions
- DRUG: Cyclophosphamide
- DRUG: Doxorubicin
- DRUG: Vincristine
- DRUG: Rituximab
- DRUG: Prednisone
- DRUG: Bendamustine
- DRUG: Lenalidomide
- DRUG: Fludarabine
- DRUG: Liso-cel
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Collaborators